HEALTHY U CHIP

PRIOR AUTHORIZATION REQUEST FORM

LONG ACTING TACROLIMUS

Astagraf XL®, Envarsus XR®

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

lf y	ou have prior authorization questions, please call for assistance 385	5-425-5	094.		
Dis	claimer: Prior authorization request forms are subject to change in accord	dance wi	th Fede	ral and State notice requirements.	
Dat	te: Member Name:	Member Name:		ID#:	
DO	B: Gender:	Gender:		Physician:	
Off	Fice Phone: Office Fax:	Office Fax:		Office Contact:	
He	ight/Weight:				
rea Pro	eferred products has not been successful, you must submit which preferred is not failure. Reasons for failure must meet the Health Plan medical not product being request: Astagraf XL® (tacrolimus extended-release), Ensing/Frequency:	ecessity	criteria		
	If the request is for reauthorization, proceed to	o reaut	horizat	ion section	
	Questions	Yes	No	Comments/Notes	
1.	Will tacrolimus extended-release be used for the prevention of organ rejection in a kidney transplant recipient?				
2.	Will tacrolimus extended-release be in used in combination with other immunosuppressants?				
3.	Is the requesting provider a nephrologist or transplant specialist?				
4.	Is the member on a stable dose of tacrolimus immediate release with whole blood trough concentrations at goal?			Please provide documentation	
	with whole blood trough concentrations at goal?			Please provide documentation Please provide documentation	
	with whole blood trough concentrations at goal? Has the member had at least a 3-month trial and failure or			•	
5.	with whole blood trough concentrations at goal? Has the member had at least a 3-month trial and failure or intolerance/contraindication to immediate-release tacrolimus?			•	
5.	with whole blood trough concentrations at goal? Has the member had at least a 3-month trial and failure or intolerance/contraindication to immediate-release tacrolimus? REAUTHORIZATION			•	
5. 1.	with whole blood trough concentrations at goal? Has the member had at least a 3-month trial and failure or intolerance/contraindication to immediate-release tacrolimus? REAUTHORIZATION Is the request for reauthorization of therapy? Has the member's therapy been re-evaluated within the past 6			•	

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.				
Additional information:				
Physician's Signature:				

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy: PHARM-CHIP-043 Origination Date: 07/01/2024 Reviewed/Revised Date: Next Review Date:

Current Effective Date: 07/01/2024

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.